Apelin Peptides and the APJ Receptor: The Apelinergic System in Cardiovascular, Metabolic, and Aging Research

Introduction: A Peptide System at the Crossroads of Modern Research

The apelin (PMID: 42660311)ergic system — comprising the apelin (PMID: 42660311) peptide family, the related peptide ELABELA (also called Toddler/Apela), and their shared G protein-coupled receptor APJ (APLNR) — has emerged as one of the most actively investigated peptide signaling axes in biomedical research. Since the discovery of apelin in 1998, over 3,000 peer-reviewed publications have explored this system's roles in cardiovascular physiology, fluid homeostasis, metabolic regulation, and the biology of aging.

What makes the apelinergic system particularly compelling for research is its breadth: apelin peptides participate in vasodilation, cardiac contractility, angiogenesis, glucose metabolism, fluid balance, and muscle regeneration. Unlike many peptide systems that operate within narrow physiological domains, the apelin/APJ axis functions as a central integrator across multiple organ systems — positioning it as a uniquely versatile research tool for investigating complex biological processes.

This guide provides a comprehensive overview of the apelinergic system for research professionals, covering the molecular biology of apelin isoforms and the APJ receptor, key signaling pathways, the relationship with the renin-angiotensin system, and the most promising research frontiers.

---

Discovery and Historical Context

The Orphan Receptor APJ

The story of apelin begins not with the peptide itself, but with its receptor. In 1993, O'Dowd and colleagues identified a novel orphan G protein-coupled receptor (GPCR) through sequence homology screening. This receptor shared approximately 40–50% amino acid identity with the angiotensin II type 1 receptor (AT1R) in its transmembrane domains — leading to its initial designation as APJ (Angiotensin receptor-like 1, or "putative receptor related to the AT1 receptor") (O'Dowd et al., 1993).

Despite the structural resemblance to AT1R, APJ did not bind angiotensin II, leaving it classified as an orphan receptor for five years.

Identification of Apelin

In 1998, Tatemoto and colleagues at Gunma University and Takeda Pharmaceutical Company identified the endogenous ligand for APJ through systematic screening of bovine stomach tissue extracts. They named the peptide apelin — a portmanteau of "APJ Endogenous LIgaNd" (Tatemoto et al., 1998). The discovery revealed that apelin is derived from a 77-amino-acid precursor, pre-proapelin, which undergoes proteolytic processing to generate multiple bioactive isoforms.

Discovery of ELABELA

The apelinergic system was expanded significantly in 2013 when two independent research groups identified a second endogenous ligand for the APJ receptor: ELABELA (also termed Toddler or Apela). Chng et al. demonstrated that ELABELA is a 54-amino-acid peptide essential for cardiovascular development, signaling through APJ independently of apelin ([Chng et al., 2013]()). This discovery reframed the apelinergic system as a dual-ligand signaling axis.

---

Molecular Biology of Apelin Peptides

Pre-Proapelin Processing and Isoforms

The human APLN gene, located on chromosome Xq25-q26.1, encodes the 77-amino-acid precursor pre-proapelin. Endopeptidase-mediated cleavage of this precursor generates several bioactive C-terminal fragments that share a conserved 12-amino-acid core but differ in N-terminal extensions:

• •Apelin-36: The longest commonly studied isoform (amino acids 42–77 of pre-proapelin)
• •Apelin-17: An intermediate isoform showing high biological potency
• •Apelin-13: The most commonly investigated isoform in laboratory research, consisting of the C-terminal 13 residues (QRPRLSHKGPMPF)
• •[Pyr¹]-Apelin-13: A pyroglutaminated form of apelin-13, where the N-terminal glutamine is cyclized — this is the predominant circulating form and shows enhanced metabolic stability

All isoforms share the critical C-terminal phenylalanine residue (Phe-13) that is essential for receptor activation. The C-terminal RPRL motif constitutes the minimal sequence required for APJ binding, though shorter fragments show markedly reduced potency (Medhurst et al., 2003). Research demonstrates that apelin-13 and apelin-17 generally exhibit stronger receptor binding affinity and more potent biological activity than apelin-36, likely due to more efficient access to the receptor binding pocket (Hosoya et al., 2000).

ELABELA: The Second Endogenous Ligand

ELABELA is encoded by the APELA gene on chromosome 4q32.3 and processed from a 54-amino-acid precursor into active fragments, primarily ELABELA-32 and ELABELA-21. Unlike apelin, which shares no sequence homology with ELABELA, both peptides converge on the APJ receptor but activate distinct downstream signaling profiles. ELABELA shows particularly important roles in embryonic development, where it is required for cardiovascular morphogenesis — functions that apelin knockout alone does not fully recapitulate ([Chng et al., 2013]()).

---

The APJ Receptor: Structure and Signaling

Receptor Architecture

The APJ receptor (gene symbol: APLNR) is a class A (rhodopsin-like) GPCR comprising 380 amino acids arranged in the canonical seven-transmembrane (7TM) domain topology. Despite its original identification based on sequence similarity to AT1R, APJ is now classified in a distinct pharmacological family.

Landmark structural studies have progressively revealed the molecular details of APJ activation:

• •The 2.6 Å crystal structure of human APJ in complex with a 17-amino-acid apelin mimetic peptide demonstrated that the ligand binds deep within the transmembrane bundle, with the C-terminal residues reaching into the receptor core (Ma et al., 2017)
• •Cryo-EM structures published in 2022 and 2025 revealed that APJ can exist as both monomeric and dimeric complexes with Gi proteins, with apelin-13 binding exclusively to one protomer in the dimeric state — a finding with significant implications for understanding receptor pharmacology ([Yue et al., 2022](); Yue et al., 2025)

Downstream Signaling Pathways

APJ couples primarily to Gαi/o proteins, but also engages Gq/11 and β-arrestin pathways depending on the ligand, cell type, and physiological context. The major signaling cascades include:

Gαi/o-Mediated Signaling:

• •Inhibition of adenylyl cyclase and suppression of cAMP/PKA activity
• •Activation of PI3K/Akt pathway — a central mediator of cell survival and anti-apoptotic signaling
• •Stimulation of eNOS (endothelial nitric oxide synthase) leading to NO-dependent vasodilation

Gq/11-Mediated Signaling:

• •Activation of phospholipase C (PLC) and inositol trisphosphate (IP3) generation
• •Intracellular calcium mobilization
• •Protein kinase C (PKC) activation leading to ERK1/2 MAPK signaling

β-Arrestin Recruitment:

• •Receptor internalization and desensitization
• •G protein-independent ERK activation
• •Scaffolding of additional signaling complexes

Critically, different apelin isoforms and ELABELA activate these pathways with distinct biases. Research by Bai et al. (2021) demonstrated that apelin-36, apelin-17, apelin-13, ELABELA-32, and ELABELA-21 act on different phosphorylation sites at the C-terminal of APJ, producing ligand-specific signaling "fingerprints" ([Bai et al., 2021]()). This concept of biased agonism at APJ is central to current drug design efforts aimed at selectively activating beneficial pathways while minimizing unwanted effects.

Mechanosensing Properties

A unique feature of APJ among GPCRs is its ability to function as a mechanosensor — the receptor can be activated by mechanical stretch in the absence of any peptide ligand. This stretch-activated signaling preferentially engages β-arrestin-dependent pathways over G protein signaling and has been implicated in cardiac remodeling under conditions of pressure overload (Zhang et al., 2024). This mechanosensory property distinguishes APJ from virtually all other peptide-activated GPCRs and adds considerable complexity to understanding its physiological roles.

---

Interaction with the Renin-Angiotensin System

One of the most research-relevant aspects of the apelinergic system is its intimate crosstalk with the renin-angiotensin system (RAS). The apelin/APJ axis functions as a counter-regulatory system to the angiotensin II/AT1R axis at multiple levels:

Functional Antagonism

APJ and AT1R are frequently co-expressed in the same tissues — including vascular endothelium, cardiac myocytes, and renal tubular epithelium. When co-expressed, APJ can directly inhibit AT1R signaling through allosteric trans-inhibition: the formation of APJ-AT1R heterodimers suppresses angiotensin II-mediated Gq coupling and downstream vasoconstriction (Chun et al., 2008).

ACE2 Connection

The apelinergic and RAS systems converge on angiotensin-converting enzyme 2 (ACE2). Apelin promotes ACE2 transcription, increasing ACE2 protein levels and activity. Since ACE2 degrades angiotensin II into the vasodilatory peptide angiotensin-(1-7), apelin effectively amplifies the protective arm of the RAS (Sato et al., 2020). Conversely, ACE2 also cleaves the C-terminal phenylalanine from apelin peptides, partially inactivating them — establishing a reciprocal regulatory loop between the two systems.

This bidirectional interaction has generated substantial research interest, particularly regarding cardiovascular remodeling and fluid homeostasis models.

---

Research Applications and Frontiers

Cardiovascular Research

Cardiovascular biology represents the most extensively studied domain for apelinergic signaling. Key research areas include:

Cardiac Contractility and Remodeling: In vitro and ex vivo studies demonstrate that apelin peptides produce concentration-dependent positive inotropic effects (increased cardiac contractility) via PI3K/Akt-dependent mechanisms. A 2026 systematic review and meta-analysis of preclinical ischemia/reperfusion models confirmed that apelin treatment significantly reduces infarct size and preserves contractile function across multiple experimental paradigms (Rostamzadeh et al., 2026).

Vascular Biology: Apelin is one of the most potent endogenous vasodilatory peptides identified to date. In vitro studies on isolated vascular preparations show that apelin-13 and apelin-36 promote concentration-dependent vasodilation through NO and prostacyclin release from endothelial cells. This vasodilatory activity has been confirmed across multiple vascular bed preparations (Pitkin et al., 2010).

Angiogenesis: APJ is expressed on endothelial tip cells during sprouting angiogenesis. In vitro models demonstrate that apelin promotes endothelial cell proliferation, migration, and tube formation — processes mediated through VEGF-independent pathways (Kidoya et al., 2008). This pro-angiogenic activity has made apelin a subject of investigation in vascular development and tissue repair models.

Metabolic Research

The apelinergic system is deeply integrated with metabolic homeostasis:

Glucose Metabolism: In vitro and cell-based assay systems demonstrate that apelin enhances glucose uptake through AMPK-dependent translocation of GLUT4 to the plasma membrane — a mechanism parallel to, but independent of, insulin signaling (Dray et al., 2008). Research on apelin's role in glucose homeostasis continues to expand, with particular interest in how the apelinergic system interacts with incretin pathways investigated by GLP-1 receptor agonists.

Adipose Tissue Biology: Apelin is classified as an adipokine — it is abundantly expressed and secreted by white adipose tissue. In cell culture models, apelin modulates adipocyte differentiation and lipid metabolism. The APLN gene is upregulated in adipocytes by insulin and tumor necrosis factor-α (TNF-α), linking apelin expression to metabolic and inflammatory states.

Aging and Sarcopenia Research

Perhaps the most exciting recent development in apelinergic research involves aging biology. A landmark 2018 study published in Nature Medicine identified apelin as an exerkine — a signaling molecule released during physical exercise that mediates systemic benefits. Vinel et al. demonstrated that apelin levels decline with age, correlating with progressive loss of muscle mass and function. Critically, the study showed that exogenous apelin administration in aged model systems enhanced mitochondrial biogenesis, promoted muscle stem cell function, and reversed markers associated with sarcopenia (Vinel et al., 2018).

These findings position apelin at the intersection of exercise biology, muscle regeneration, and geroscience — research areas of considerable current interest. The identification of apelin as a potential biomarker for early sarcopenia detection adds diagnostic utility to its biological significance, complementing research on other anti-aging peptides and mitochondrial-derived peptides.

Fluid Balance and Neuroendocrine Research

Apelin and its receptor are highly expressed in hypothalamic nuclei that regulate fluid homeostasis. Research demonstrates that the apelinergic system functions as a physiological counter-regulator to arginine vasopressin (AVP), the primary antidiuretic hormone:

• •In isolated collecting duct preparations, apelin inhibits AVP-stimulated water reabsorption by reducing aquaporin-2 trafficking to the apical membrane
• •The apelin/AVP ratio serves as a research biomarker for fluid balance status

The development of metabolically stable apelin analogs such as LIT01-196 — a modified apelin-17 that resists enzymatic degradation — has enabled extended studies of aquaretic (water-excreting) effects in experimental fluid balance models (Flahault et al., 2021; Flahault et al., 2021).

Pulmonary Vascular Research

The apelinergic system has emerged as a significant focus in pulmonary vascular biology. Reduced apelin expression and signaling have been documented in experimental models of pulmonary vascular remodeling. APJ is abundantly expressed on pulmonary endothelial cells, and in vitro studies demonstrate that apelin promotes endothelial survival and suppresses proliferative vascular remodeling through Akt/eNOS-dependent mechanisms (Kim et al., 2014).

---

Pharmacological Tools and Research Compounds

Peptide Agonists

The endogenous apelin isoforms themselves serve as primary research tools:

Stabilized Analogs

A critical challenge in apelinergic research is the rapid enzymatic degradation of native apelin peptides — plasma half-life measurements indicate clearance on the order of minutes, primarily through ACE2-mediated removal of the C-terminal phenylalanine and neprilysin-catalyzed cleavage. Several stabilized analogs have been developed as research tools:

• •LIT01-196: A metabolically stable apelin-17 analog incorporating fluorocarbon chain modifications at the N-terminus. This compound resists ACE2 degradation and maintains full APJ agonist activity with a dramatically extended in vitro half-life (Flahault et al., 2021)
• •MM07 (CMF-019 analog): A modified apelin-13 analog with enhanced metabolic stability, used extensively in structure-activity relationship (SAR) studies
• •Pyr-Ala-Pro-[D-Ala¹³]-apelin-13: Features D-amino acid substitution at the ACE2 cleavage site to confer protease resistance

Small-Molecule APJ Agonists

The pharmaceutical research community has invested substantially in developing non-peptide APJ agonists with improved oral bioavailability. Notable small-molecule research tools include BMS-986224, which has been characterized in vitro and in vivo as a potent, selective APJ agonist ([Ason et al., 2020]()). Structure-based drug design using the APJ crystal and cryo-EM structures has accelerated the identification of novel small-molecule scaffolds, demonstrating the translational value of structural biology approaches in apelinergic research.

Antagonists

• •ML221: A selective small-molecule APJ antagonist widely used as a pharmacological tool to confirm APJ-dependent mechanisms in cell-based assays
• •F13A (apelin-13 F→A): A modified apelin-13 where the C-terminal phenylalanine is replaced with alanine, converting it from agonist to competitive antagonist — a critical tool for receptor pharmacology studies

---

Research Considerations and Methodological Notes

Isoform Selection

The choice of apelin isoform significantly impacts experimental outcomes. Apelin-13 and [Pyr¹]-apelin-13 are recommended for most in vitro receptor activation studies due to their high potency and well-characterized pharmacology. Apelin-36 may be preferred for studies investigating isoform-dependent signaling bias or endosomal signaling, as its longer N-terminal sequence affects receptor binding kinetics and internalization dynamics.

Stability and Handling

Native apelin peptides are highly susceptible to enzymatic degradation. For in vitro applications:

• •Reconstitute in sterile, deionized water or phosphate-buffered saline (pH 7.4)
• •Avoid repeated freeze-thaw cycles; aliquot working stocks upon reconstitution
• •Include protease inhibitor cocktails when working with biological matrices containing ACE2 or neprilysin activity
• •Consider [Pyr¹]-apelin-13 or stabilized analogs (e.g., LIT01-196) for extended incubation protocols

For detailed guidance on peptide handling, consult our peptide storage best practices and reconstitution guide.

Receptor Expression Verification

APJ expression varies significantly across cell lines and tissue preparations. Researchers should verify APJ expression in their experimental system using RT-qPCR, Western blot, or radioligand binding assays before attributing observed effects to apelinergic signaling. The ML221 antagonist and F13A peptide provide essential pharmacological controls for confirming APJ specificity.

Purity and Quality Assessment

Given the structural importance of the C-terminal phenylalanine for apelin bioactivity, researchers should verify peptide integrity by mass spectrometry and HPLC analysis before use. Even minor degradation products (e.g., des-Phe apelin fragments) can confound results by acting as partial agonists or antagonists. A thorough understanding of how to read a Certificate of Analysis is essential.

---

Current Research Landscape and Future Directions

The apelinergic field is advancing rapidly on several fronts:

Biased Agonism and Selective Signaling: The discovery that different apelin isoforms and ELABELA activate distinct signaling fingerprints at APJ has opened the door to designing biased agonists — compounds that selectively activate beneficial pathways (e.g., Gi/PI3K/Akt for cardioprotection) while avoiding potentially deleterious effects (e.g., β-arrestin-mediated desensitization or hypertrophic signaling) (Narayanan et al., 2015). This represents a sophisticated approach to apelinergic pharmacology.

Combinatorial Approaches: Emerging research explores synergistic interactions between apelinergic signaling and other peptide systems, including the GLP-1 receptor pathway. Preclinical studies investigating APJ agonists in combination with semaglutide and related GLP-1 receptor agonists have shown enhanced metabolic and cardiovascular readouts compared to either agent alone.

Structural Biology Revolution: The availability of high-resolution crystal and cryo-EM structures of APJ in multiple activation states — monomeric, dimeric, agonist-bound, and antagonist-bound — provides an unprecedented foundation for rational drug design. These structures have already enabled the design of non-hypertrophic APJ modulators that can dissociate beneficial cardioprotective effects from unwanted cardiac remodeling.

Aging and Exerkine Biology: The identification of apelin as an exercise-induced myokine that declines with age positions it as a key molecule in the rapidly growing field of exerkine biology. Ongoing research investigates whether sustained APJ activation can replicate some of the systemic benefits of physical exercise in aged experimental systems — a concept with broad implications for geroscience.

---

Summary

The apelinergic system represents one of the most dynamic and multi-faceted peptide signaling axes under current investigation. From its origins as an orphan receptor in 1993 to the present-day landscape of cryo-EM structures, biased agonist design, and exerkine biology, the apelin/ELABELA/APJ axis continues to reveal new dimensions of physiology relevant to cardiovascular, metabolic, and aging research.

For research professionals, the apelinergic system offers a rich toolkit of endogenous peptide isoforms, stabilized analogs, small-molecule agonists and antagonists, and detailed structural data — all supported by a robust and growing literature base. As understanding of biased signaling and receptor dimerization deepens, the opportunities for precision pharmacology within this system will only expand.

---

Research Tools

Researchers sourcing this peptide for laboratory investigation can use the peptide price comparison tool to identify research-grade material from verified suppliers. For reconstitution planning, the peptide calculator provides molar mass, concentration, and dilution calculations.

References

1. O'Dowd BF, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993;136(1-2):355-360. PubMed

2. Tatemoto K, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251(2):471-476. PubMed

3. Habata Y, et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta. 1999;1452(1):25-35. PubMed

5. Ma Y, et al. Structural basis for apelin control of the human apelin receptor. Structure. 2017;25(6):858-866. PubMed

7. Yue Y, et al. Structural insights into the regulation of monomeric and dimeric apelin receptor. Nat Commun. 2025;16:271. DOI

9. Zhang H, et al. Structure-based design of non-hypertrophic apelin receptor modulator. Cell. 2024;187(6):1460-1475. DOI

10. Chun HJ, et al. The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. J Biol Chem. 2008;283(17):11942-11955. PubMed

11. Sato T, et al. Interaction between the apelinergic system and ACE2 in the cardiovascular system: therapeutic implications. Clin Sci. 2020;134(17):2319-2336. PubMed

12. Vinel C, et al. The exerkine apelin reverses age-associated sarcopenia. Nat Med. 2018;24(9):1360-1371. PubMed

13. Kim J. Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension. Mol Cells. 2014;37(3):196-201. PubMed

14. Flahault A, et al. LIT01-196, a metabolically stable apelin-17 analog, normalizes blood pressure in hypertensive DOCA-salt rats via a NO synthase-dependent mechanism. Front Pharmacol. 2021;12:715095. PubMed

15. Narayanan S, et al. Regulation of the apelinergic system and its potential in cardiovascular disease. J Med Chem. 2015;58(20):7913-7927. PubMed

16. Rostamzadeh F, et al. Cardioprotective effects of apelin in myocardial ischemia/reperfusion injury: a systematic review and meta-analysis. Basic Res Cardiol. 2026. PubMed

17. Medhurst AD, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84(5):1162-1172. PubMed

18. Simpkin JC, et al. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol. 2007;102(6):518-528. PubMed

20. Chapman FA, et al. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J Endocrinol. 2013;219(1):R13-R35. PubMed

---

Further Reading:

• •Orexin A and Orexin B (Hypocretins): The Hypothalamic Neuropeptides Governing Arousal, Metabolism, and Oncology Research
• •Oxytocin: The Nonapeptide Redefining Neuroendocrine and Social Behavior Research
• •Galanin: The Pleiotropic Neuropeptide Bridging Neuroscience, Metabolic, Pain, and Oncology Research
• •Natriuretic Peptides (ANP, BNP, CNP): The Cardiac Hormone Family Governing Cardiovascular, Renal, and Metabolic Research
• •Reconstitution Calculator
• •Peptide Stack Builder

---

All compounds discussed in this article are intended for laboratory research use only (RUO). They are not approved for human or veterinary use and are not intended for food or cosmetic applications. Researchers must comply with all applicable institutional, local, and national regulations governing the use of research chemicals.